胎盘部位滋养细胞肿瘤保留生育功能治疗的临床特征与生育结局回顾性分析
本研究回顾性分析北京协和医院1998年4月至2020年4月收治的126例胎盘部位滋养细胞肿瘤(PSTT)患者,其中29例接受保留生育功能治疗。保留生育功能治疗组年龄显著更轻、足月产史比例更低,分期、血清β-hCG水平及距前次妊娠间隔无显著差异;所有保留生育功能治疗患者均获完全缓解且随访36至176个月无复发,并获16次健康足月分娩。
要点
- 126例PSTT患者中29例接受保留生育功能治疗,均无挽救性子宫切除。
- 保留生育功能治疗组年龄更轻、足月产史比例更低,其余基线无显著差异。
- 保留生育功能治疗未显著延长化疗时长,随访36至176个月无复发。
核心结论
- 对于有强烈保留生育意愿的年轻、子宫病灶局限的PSTT患者,可考虑保留生育功能治疗。
- 采用个体化保守手术及选择性辅助化疗,保留生育功能治疗不影响复发风险或总生存,患者可获得良好的妊娠及活产结局。
研究设计与样本
- 回顾性收集1998年4月至2020年4月北京协和医院诊断为PSTT的患者临床资料,共纳入126例,其中29例接受保留生育功能治疗,并与子宫切除患者进行比较。
主要发现
- 保留生育功能治疗组较子宫切除组年龄显著更轻、前次足月分娩比例显著更低,两组分期、血清β-hCG水平及距前次妊娠间隔无显著差异。
- 保留生育功能治疗组无患者接受挽救性子宫切除;有临床或病理高危因素者接受辅助化疗,保留生育功能治疗未显著延长化疗时长。
- 保留生育功能治疗组全部患者达完全缓解,随访36至176个月无复发,治疗结束1年后共获得16次健康足月分娩。
关键数值与推荐
- 保留生育功能治疗适用于年轻、子宫病灶局限且强烈希望保留生育潜能的PSTT患者。
- 保守手术方式个体化选择,临床或病理高危因素者接受辅助化疗。
临床怎么用
- 作者认为,对年轻、病灶局限且强烈希望保留生育功能的PSTT患者可考虑保留生育功能治疗。
- 作者指出,在个体化保守手术联合选择性辅助化疗下,保留生育功能治疗不影响复发风险或总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the methods, feasibility, efficiency, and fertility outcomes of fertility-sparing treatment for patients with placental site trophoblastic tumor (PSTT). METHODS: Clinical data of patients diagnosed with PSTT between April 1998 and April 2020 from Peking Union Medical College Hospital (PUMCH) were retrospectively collected. The clinical features, treatment, and outcomes of patients received fertility-sparing treatment were analyzed and compared with patients suffered hysterectomy. RESULTS: In total, 126 patients were included in the study and 29 of them received fertility-sparing treatment. Besides significantly younger age and lower proportion of antecedent term delivery were seen in fertility-sparing group than hysterectomy group, no significant differences were observed in stage, serum β-hCG level, or interval from antecedent pregnancy between the two groups. Conservative surgery was selected individualized and none of them suffered salvage hysterectomy. Patients with clinical or pathological high-risk factors received adjuvant chemotherapy, yet the fertility-sparing treatment did not significantly lengthen chemotherapy duration. All patients in fertility-sparing group achieved complete remission without relapse after 36 to 176 months of follow-up and had sixteen healthy term delivery more than one year after the treatment. CONCLUSIONS: Fertility-sparing treatment for PSTT can be considered for young patients with localized uterine lesions who strongly desire to preserve their fertility potential. With individualized conservative surgery and selected adjuvant chemotherapy, fertility-sparing treatment will not influence the risk of relapse or overall survival and patients will achieve favorable pregnancy and live birth outcomes.
引用
- Jiang S, Zhao J, Shi X, et al. Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor. Gynecol Oncol. 2023. PMID: 36804610. doi:10.1016/j.ygyno.2023.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。